Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6233022 | Journal of Affective Disorders | 2014 | 6 Pages |
BackgroundThis analysis investigated the correlations between the efficacy of olanzapine monotherapy and the number of concurrent manic symptoms in patients treated for bipolar depression.MethodsPooled data from 2 placebo-controlled olanzapine studies in patients with bipolar I depression were analyzed (total 1214 patients; 690 olanzapine monotherapy patients and 524 placebo patients). Patients were categorized for mixed features by the number of concurrent manic symptoms at baseline (0, 1 or 2, and â¥3, respectively, as measured by a Young Mania Rating Scale item score â¥1). Efficacy was evaluated by change in Montgomery-à sberg Depression Rating Scale (MADRS) total score from baseline to 6 weeks.ResultsLeast-squares mean differences between olanzapine and placebo in the change of MADRS total scores were â3.76 (p=0.002), â3.20 (p<0.001), and â3.44 (p=0.002) for mixed features 0, 1 or 2, and â¥3, respectively. The response rates for olanzapine versus (vs.) placebo were 52.6% vs. 39.8%, 50.3% vs. 40.0%, and 42.2% vs. 33.7% for mixed features 0, 1 or 2, and â¥3, respectively. The remission rates for olanzapine vs. placebo group were 46.1% vs. 34.3%, 39.5% vs. 32.0%, and 34.8% vs. 24.1% for mixed features 0, 1 or 2, and â¥3, respectively. No significant interaction between mixed features and treatment was seen in the MADRS changes or response and remission rates.LimitationsPost hoc analyses of the data from 2 previous randomized clinical studies.ConclusionsOlanzapine monotherapy was shown to be effective in the treatment of bipolar depression irrespective of the presence of concurrent manic symptoms.